High-risk Non-muscle Invasive Bladder Cancer research hub
6 indexed studies · 5 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
This early-stage study looks at a treatment called IMUNO BCG Moreau RJ for adults with high-risk bladder cancer that has not grown into the bladder muscle. Doctors want to see if placing this medicine into the bladder after surgery stops the cancer from returning or getting worse over two years.
Spain - recruitingPhase III
A randomised Phase III trial to assess whether radiotherapy with radiosensitisers is beneficial in patients with high-risk non-muscle invasive bladder cancer when compared with the standard of care treatment, Bacillus Calmette-Guerin
This study compares two treatments for high-risk bladder cancer that hasn't spread to the muscle: standard treatment (BCG immunotherapy) versus a new approach combining radiotherapy with special drugs. We want to see if the new approach works better to prevent cancer recurrence or progression.
United Kingdom · England - recruitingPhase III
A phase 3, randomized, open-label, multicenter study evaluating the efficacy and safety of TAR-210 erdafitinib intravesical delivery system versus investigator’s choice of intravesical chemotherapy in participants with high-risk non-muscle-invasive bladder cancer with susceptible FGFR alterations who had received intravesical Bacillus Calmette-Guérin (BCG)
This study looks at a new bladder cancer treatment called TAR-210 for people with high-risk, early-stage bladder cancer that hasn't spread to the muscle. It compares TAR-210 to standard chemotherapy to see which works best and is safest. You might be able to join if you've had a type of chemotherapy called BCG.
United Kingdom · Argentina · Belgium - recruitingPhase III
Is Gem-Doce an alternative to BCG treatment for people with early bladder cancer?
This study compares a new treatment called Gem-Doce with the usual BCG treatment for early bladder cancer. It aims to see if Gem-Doce works as well as BCG but with fewer side effects, offering a potentially better option for patients.
United Kingdom · England · Scotland - active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
This study is looking into a new treatment for a type of bladder cancer called high-risk non-muscle invasive bladder cancer. It combines a drug called pembrolizumab with an existing treatment, BCG, to see if it works better and is safe.
United States · Australia · Austria - not yet recruitingPHASE3
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
This study compares two ways to treat high-risk bladder cancer that hasn't spread: standard BCG therapy (a medicine put into the bladder) versus a combination of radiotherapy and a special drug to make it work better. It aims to find a more effective and reliable treatment.
United Kingdom